Tamarse, Marielle .
HRN: 28-12-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/17/2025
CO-AMOXICLAV 625MG (TAB)
12/17/2025
12/24/2025
ORAL
625mg
BID
PROM
Checking Final Appropriateness
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes